A benefit/risk assessment of existing therapeutic alternatives for the treatment of painful inflammatory conditions

被引:1
|
作者
Ehrlich, GE [1 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] NYU, Philadelphia, PA USA
关键词
non-steroidal anti-inflammatory drugs; benefit/risk; adverse events; COX-2; inhibitors; nimesulide;
D O I
10.1111/j.1742-1241.2004.020_d.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pain remains the leading reason for which patients consult their doctors. Pain also motivates over-the-counter sales of analgesic medicines, to be taken orally or even transcutaneously. Prescription medicines usually follow attempts at self-medication that fail to achieve the desired results. Acute pain usually subsides spontaneously but medicines are needed until that occurs; in arthritic conditions sigma especially osteoarthritis sigma anti-inflammatory drugs work best in short-term administration for flares that aggravate chronic but tolerable pain. In cases of chronic pain that exceeds the level of easy tolerance, anti-inflammatory drugs can reduce the pain to tolerable levels more effectively than simple analgesics and narcotic combinations. The non-steroidal anti-inflammatory drugs (NSAIDs) are among the most useful medicines providing an array of drugs that differ chiefly in time of onset of action, duration of action and persistence in the blood. The benefit they provide is pain amelioration; none is curative. The risks are well known and do not differ greatly among the drugs; unwanted gastrointestinal (GI) effects are the most common, but the skin, kidneys, liver and blood forming organs may also be affected. As the benefits are similar, when balancing risk and benefit it is important to: consider the cause and expected duration of pain, balance the risks (GI unwanted effects far outnumber others), assess the severity and likelihood of specific reactions, and consider the costs sigma not only of the medicines themselves but also those of treating untoward reactions. Thus NSAIDs number among the most successful therapeutic options of modem medicine and, as pain will continue to require intervention, will likely continue sigma at least as ancillary medications sigma even as more definitive treatments are developed. In addition, the target population, its characteristics and the duration and acceptance of the intervention need to be considered.
引用
收藏
页码:20 / 26
页数:7
相关论文
共 50 条
  • [1] Methods of therapeutic benefit-risk assessment
    Moride, Yola
    Lynd, Larry
    Abenhaim, Lucien
    Moore, L.
    Kurz, Xavier
    Hartford, Craig
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S1 - S1
  • [2] Emerging contaminants in wastewater: A critical review on occurrence, existing legislations, risk assessment, and sustainable treatment alternatives
    Parida, Vishal Kumar
    Saidulu, Duduku
    Majumder, Abhradeep
    Srivastava, Ashish
    Gupta, Bramha
    Gupta, Ashok Kumar
    JOURNAL OF ENVIRONMENTAL CHEMICAL ENGINEERING, 2021, 9 (05):
  • [3] DICLOFENAC/MISOPROSTOL - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN PAINFUL INFLAMMATORY CONDITIONS
    DAVIS, R
    YARKER, YE
    GOA, KL
    DRUGS & AGING, 1995, 7 (05) : 372 - 393
  • [4] Lornoxicam - A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions
    Balfour, JA
    Fitton, A
    Barradell, LB
    DRUGS, 1996, 51 (04) : 639 - 657
  • [5] RISK-BENEFIT ASSESSMENT OF DRUGS USED IN THE TREATMENT OF INFLAMMATORY BOWEL-DISEASE
    HANAUER, SB
    STATHOPOULOS, G
    DRUG SAFETY, 1991, 6 (03) : 192 - 219
  • [6] A Multiattribute Model for Evaluating the Benefit-Risk Profiles of Treatment Alternatives
    Felli, James C.
    Noel, Rebecca A.
    Cavazzoni, Patrizia A.
    MEDICAL DECISION MAKING, 2009, 29 (01) : 104 - 115
  • [7] Benefit–Risk Assessment of Diacerein in the Treatment of Osteoarthritis
    Elena Panova
    Graeme Jones
    Drug Safety, 2015, 38 : 245 - 252
  • [8] Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
    Priya Sumithran
    Joseph Proietto
    Drug Safety, 2014, 37 : 597 - 608
  • [9] Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
    Sumithran, Priya
    Proietto, Joseph
    DRUG SAFETY, 2014, 37 (08) : 597 - 608
  • [10] Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis
    Schmidt, H
    Woodcock, BG
    Geisslinger, G
    DRUG SAFETY, 2004, 27 (03) : 185 - 196